BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bhandari S, Watson N, Long E, Sharpe S, Zhong W, Xu SZ, Atkin SL. Expression of somatostatin and somatostatin receptor subtypes 1-5 in human normal and diseased kidney. J Histochem Cytochem 2008;56:733-43. [PMID: 18443363 DOI: 10.1369/jhc.2008.950998] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Qian Q, Wang HY. ALADIN: wish granted in inherited polycystic kidney disease? Lancet 2013;382:1469-71. [PMID: 23972262 DOI: 10.1016/S0140-6736(13)61541-X] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
2 Hama T, Park F. Heterotrimeric G protein signaling in polycystic kidney disease. Physiol Genomics 2016;48:429-45. [PMID: 27199453 DOI: 10.1152/physiolgenomics.00027.2016] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
3 Hu YY, Dong WD, Xu YF, Yao XD, Peng B, Liu M, Zheng JH. Elevated levels of miR-155 in blood and urine from patients with nephrolithiasis. Biomed Res Int 2014;2014:295651. [PMID: 25197634 DOI: 10.1155/2014/295651] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
4 Meijer E, Drenth JP, d’Agnolo H, Casteleijn NF, de Fijter JW, Gevers TJ, Kappert P, Peters DJ, Salih M, Soonawala D. Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2014;63:446-455. [PMID: 24342522 DOI: 10.1053/j.ajkd.2013.10.011] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 5.6] [Reference Citation Analysis]
5 Jiang HN, Zeng B, Zhang Y, Daskoulidou N, Fan H, Qu JM, Xu SZ. Involvement of TRPC channels in lung cancer cell differentiation and the correlation analysis in human non-small cell lung cancer. PLoS One 2013;8:e67637. [PMID: 23840757 DOI: 10.1371/journal.pone.0067637] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 5.1] [Reference Citation Analysis]
6 Abdellatif AAH. A plausible way for excretion of metal nanoparticles via active targeting. Drug Dev Ind Pharm 2020;46:744-50. [PMID: 32250174 DOI: 10.1080/03639045.2020.1752710] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
7 Dalmo J, Westberg E, Barregard L, Svedbom L, Johansson M, Törnqvist M, Forssell-Aronsson E. Evaluation of retinol binding protein 4 and carbamoylated haemoglobin as potential renal toxicity biomarkers in adult mice treated with (177)Lu-octreotate. EJNMMI Res 2014;4:59. [PMID: 26116120 DOI: 10.1186/s13550-014-0059-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
8 Masyuk TV, Radtke BN, Stroope AJ, Banales JM, Gradilone SA, Huang B, Masyuk AI, Hogan MC, Torres VE, Larusso NF. Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases. Hepatology 2013;58:409-21. [PMID: 23172758 DOI: 10.1002/hep.26140] [Cited by in Crossref: 76] [Cited by in F6Publishing: 72] [Article Influence: 8.4] [Reference Citation Analysis]
9 Sussman CR, Wang X, Chebib FT, Torres VE. Modulation of polycystic kidney disease by G-protein coupled receptors and cyclic AMP signaling. Cell Signal 2020;72:109649. [PMID: 32335259 DOI: 10.1016/j.cellsig.2020.109649] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
10 Messchendorp AL, Casteleijn NF, Meijer E, Gansevoort RT. Somatostatin in renal physiology and autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2020;35:1306-16. [PMID: 31077332 DOI: 10.1093/ndt/gfz054] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
11 Malik N, Moaeen-ud-Din M, Zhao R. Ontogeny of mRNA expression of somatostatin and its receptors in chicken embryos in association with methylation status of their promoters. Comp Biochem Physiol B Biochem Mol Biol 2013;165:260-70. [PMID: 23727427 DOI: 10.1016/j.cbpb.2013.05.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
12 Parihar AS, Chopra S, Prasad V. Nephrotoxicity after radionuclide therapies. Transl Oncol 2022;15:101295. [PMID: 34847420 DOI: 10.1016/j.tranon.2021.101295] [Reference Citation Analysis]
13 Lin C, Happé H, Veraar K, Scharpfenecker M, Peters DJ; Dipak Consortium. The expression of somatostatin receptor 2 decreases during cyst growth in mice with polycystic kidney disease. Exp Biol Med (Maywood) 2018;243:1092-8. [PMID: 30261745 DOI: 10.1177/1535370218803893] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
14 Wang G, Kwan BC, Lai FM, Choi PC, Chow KM, Li PK, Szeto CC. Intrarenal expression of miRNAs in patients with hypertensive nephrosclerosis. Am J Hypertens 2010;23:78-84. [PMID: 19910931 DOI: 10.1038/ajh.2009.208] [Cited by in Crossref: 90] [Cited by in F6Publishing: 93] [Article Influence: 7.5] [Reference Citation Analysis]
15 Testa F, Magistroni R. ADPKD current management and ongoing trials. J Nephrol 2020;33:223-37. [PMID: 31853789 DOI: 10.1007/s40620-019-00679-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
16 Horton TM, Allegretti PA, Lee S, Moeller HP, Smith M, Annes JP. Zinc-Chelating Small Molecules Preferentially Accumulate and Function within Pancreatic β Cells. Cell Chem Biol 2019;26:213-222.e6. [PMID: 30527998 DOI: 10.1016/j.chembiol.2018.10.019] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
17 Sharma A, Hariharan S. Octreotide Delaying the Progression of Recurrent IgA Nephropathy After Kidney Transplantation. Transplant Direct 2020;6:e518. [PMID: 32047846 DOI: 10.1097/TXD.0000000000000963] [Reference Citation Analysis]
18 Rousseau E, Lau J, Zhang Z, Uribe CF, Kuo H, Zhang C, Zeisler J, Colpo N, Lin K, Bénard F. Effects of adding an albumin binder chain on [177Lu]Lu-DOTATATE. Nuclear Medicine and Biology 2018;66:10-7. [DOI: 10.1016/j.nucmedbio.2018.08.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
19 Lupp A, Ehms B, Stumm R, Göckeritz J, Mawrin C, Schulz S. Reassessment of SST4 Somatostatin Receptor Expression Using SST4-eGFP Knockin Mice and the Novel Rabbit Monoclonal Anti-Human SST4 Antibody 7H49L61. Int J Mol Sci 2021;22:12981. [PMID: 34884783 DOI: 10.3390/ijms222312981] [Reference Citation Analysis]
20 Hagforsen E, Michaëlsson G, Stridsberg M. Somatostatin receptors are strongly expressed in palmoplantar sweat glands and ducts: studies of normal and palmoplantar pustulosis skin. Clin Exp Dermatol 2011;36:521-7. [PMID: 21564193 DOI: 10.1111/j.1365-2230.2010.03993.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
21 El-Samahy MH, Adly AA, Elhenawy YI, Ismail EA, Pessar SA, Mowafy ME, Saad MS, Mohammed HH. Urinary miRNA-377 and miRNA-216a as biomarkers of nephropathy and subclinical atherosclerotic risk in pediatric patients with type 1 diabetes. J Diabetes Complications 2018;32:185-92. [PMID: 29175120 DOI: 10.1016/j.jdiacomp.2017.10.014] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
22 Kasprzak A. Somatostatin and Its Receptor System in Colorectal Cancer. Biomedicines 2021;9:1743. [PMID: 34829972 DOI: 10.3390/biomedicines9111743] [Reference Citation Analysis]
23 Kratochwil C, Apostolidis L, Rathke H, Apostolidis C, Bicu F, Bruchertseifer F, Choyke PL, Haberkorn U, Giesel FL, Morgenstern A. Dosing 225Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity. Eur J Nucl Med Mol Imaging 2021. [PMID: 34448031 DOI: 10.1007/s00259-021-05474-1] [Reference Citation Analysis]
24 Shenoy PA, Kuo A, Khan N, Gorham L, Nicholson JR, Corradini L, Vetter I, Smith MT. The Somatostatin Receptor-4 Agonist J-2156 Alleviates Mechanical Hypersensitivity in a Rat Model of Breast Cancer Induced Bone Pain. Front Pharmacol 2018;9:495. [PMID: 29867498 DOI: 10.3389/fphar.2018.00495] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
25 Meijer E, Visser FW, van Aerts RMM, Blijdorp CJ, Casteleijn NF, D'Agnolo HMA, Dekker SEI, Drenth JPH, de Fijter JW, van Gastel MDA, Gevers TJ, Lantinga MA, Losekoot M, Messchendorp AL, Neijenhuis MK, Pena MJ, Peters DJM, Salih M, Soonawala D, Spithoven EM, Wetzels JF, Zietse R, Gansevoort RT; DIPAK-1 Investigators. Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial. JAMA 2018;320:2010-9. [PMID: 30422235 DOI: 10.1001/jama.2018.15870] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 11.8] [Reference Citation Analysis]
26 Torres VE, Harris PC. Strategies targeting cAMP signaling in the treatment of polycystic kidney disease. J Am Soc Nephrol 2014;25:18-32. [PMID: 24335972 DOI: 10.1681/ASN.2013040398] [Cited by in Crossref: 152] [Cited by in F6Publishing: 100] [Article Influence: 16.9] [Reference Citation Analysis]
27 Varecza Z, Elekes K, László T, Perkecz A, Pintér E, Sándor Z, Szolcsányi J, Keszthelyi D, Szabó A, Sándor K, Molnár TF, Szántó Z, Pongrácz JE, Helyes Z. Expression of the somatostatin receptor subtype 4 in intact and inflamed pulmonary tissues. J Histochem Cytochem 2009;57:1127-37. [PMID: 19687471 DOI: 10.1369/jhc.2009.953919] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
28 Forssell-Aronsson E, Spetz J, Ahlman H. Radionuclide therapy via SSTR: future aspects from experimental animal studies. Neuroendocrinology 2013;97:86-98. [PMID: 22572526 DOI: 10.1159/000336086] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
29 Dasgupta P, Gűnther T, Schulz S. Pharmacological Characterization of Veldoreotide as a Somatostatin Receptor 4 Agonist. Life (Basel) 2021;11:1075. [PMID: 34685446 DOI: 10.3390/life11101075] [Reference Citation Analysis]
30 Wang G, Kwan BC, Lai FM, Choi PC, Chow K, Li PK, Szeto C. Intrarenal expression of microRNAs in patients with IgA nephropathy. Lab Invest 2010;90:98-103. [DOI: 10.1038/labinvest.2009.118] [Cited by in Crossref: 83] [Cited by in F6Publishing: 84] [Article Influence: 6.4] [Reference Citation Analysis]
31 Boy C, Heusner TA, Poeppel TD, Redmann-Bischofs A, Unger N, Jentzen W, Brandau W, Mann K, Antoch G, Bockisch A, Petersenn S. 68Ga-DOTATOC PET/CT and somatostatin receptor (sst1-sst5) expression in normal human tissue: correlation of sst2 mRNA and SUVmax. Eur J Nucl Med Mol Imaging 2011;38:1224-36. [PMID: 21369945 DOI: 10.1007/s00259-011-1760-x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 62] [Article Influence: 5.9] [Reference Citation Analysis]
32 Lu YY, Gao JH, Zhao C, Wen SL, Tang CW, Wang YF. Cyclooxygenase-2 up-regulates hepatic somatostatin receptor 2 expression. Sci Rep 2018;8:11033. [PMID: 30038293 DOI: 10.1038/s41598-018-29349-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
33 Cui Y, Liu S, Cui W, Gao D, Zhou W, Luo P. Identification of potential biomarkers and therapeutic targets for human IgA nephropathy and hypertensive nephropathy by bioinformatics analysis. Mol Med Rep 2017;16:3087-94. [PMID: 28713898 DOI: 10.3892/mmr.2017.6996] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
34 Martino MCD, Hofland LJ, Lamberts SW. Somatostatin and Somatostatin Receptors: from Basic Concepts to Clinical Applications. Neuroendocrinology - Pathological Situations and Diseases. Elsevier; 2010. pp. 255-80. [DOI: 10.1016/s0079-6123(10)82011-4] [Cited by in Crossref: 33] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
35 Conen P, Pennetta F, Dendl K, Hertel F, Vogg A, Haberkorn U, Giesel FL, Mottaghy FM. [68 Ga]Ga-FAPI uptake correlates with the state of chronic kidney disease. Eur J Nucl Med Mol Imaging 2022. [PMID: 34988624 DOI: 10.1007/s00259-021-05660-1] [Reference Citation Analysis]
36 Geenen L, Nonnekens J, Konijnenberg M, Baatout S, De Jong M, Aerts A. Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [177Lu]Lu-DOTA-TATE for the treatment of neuroendocrine tumours. Nucl Med Biol 2021;102-103:1-11. [PMID: 34242948 DOI: 10.1016/j.nucmedbio.2021.06.006] [Reference Citation Analysis]
37 Potts JW, Mousa SA. Recent advances in management of autosomal-dominant polycystic kidney disease. Am J Health Syst Pharm 2017;74:1959-68. [PMID: 29167138 DOI: 10.2146/ajhp160886] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
38 Weng SC, Wu CL, Kor CT, Chiu PF, Wu MJ, Chang CC, Tarng DC. Migraine and subsequent chronic kidney disease risk: a nationwide population-based cohort study. BMJ Open 2017;7:e018483. [PMID: 29284721 DOI: 10.1136/bmjopen-2017-018483] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]